{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Androgen-insensitive+Prostate+Cancer",
    "query": {
      "condition": "Androgen-insensitive Prostate Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Androgen-insensitive+Prostate+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T20:33:51.829Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00450463",
      "title": "Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sargramostim (GM-CSF, Leukine)",
          "type": "DRUG"
        },
        {
          "name": "Flutamide (Eulexin)",
          "type": "DRUG"
        },
        {
          "name": "PROSTVAC-F/ TRICOM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PROSTVAC-V/TRICOM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "MALE",
        "summary": "18 Years to 110 Years · Male only"
      },
      "enrollment_count": 64,
      "start_date": "2007-02-23",
      "completion_date": "2017-06-08",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00450463"
    },
    {
      "nct_id": "NCT00928174",
      "title": "Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "IV administration of fluorine-18 fluorocholine followed by PET/CT imaging",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Queen's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2009-06",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2015-11-11",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00928174"
    },
    {
      "nct_id": "NCT00065442",
      "title": "Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sipuleucel-T",
          "type": "BIOLOGICAL"
        },
        {
          "name": "APC-Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dendreon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 512,
      "start_date": "2003-07",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2010-09-06",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 65,
      "location_summary": "Laguna Hills, California • Loma Linda, California • Los Angeles, California + 49 more",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00065442"
    },
    {
      "nct_id": "NCT05551117",
      "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Androgen-Independent Prostatic Cancer",
        "Androgen-Insensitive Prostatic Cancer",
        "Androgen-Resistant Prostatic Cancer",
        "Hormone Refractory Prostatic Cancer",
        "Anal Cancer",
        "Anal Neoplasm",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Head and Neck Squamous Cell Carcinoma",
        "Laryngeal Squamous Cell Carcinoma",
        "Oral Squamous Cell Carcinoma",
        "Malignant Melanoma",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Non-small Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "vobramitamab duocarmazine 2.0 mg (Arm A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vobramitamab duocarmazine 2.7 mg (Arm B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vobramitamab duocarmazine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2023-06-13",
      "completion_date": "2025-01-23",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 14,
      "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05551117"
    },
    {
      "nct_id": "NCT01450683",
      "title": "Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Neoplasms",
        "Castrate-resistant Prostate Cancer (CRPC)",
        "Androgen-insensitive Prostate Cancer",
        "Hormone-refractory Prostate Cancer",
        "Metastatic Disease"
      ],
      "interventions": [
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2010-09",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01450683"
    },
    {
      "nct_id": "NCT01020305",
      "title": "Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Neoplasms",
        "Castrate-resistant Prostate Cancer (CRPC)",
        "Androgen-insensitive Prostate Cancer",
        "Hormone-refractory Prostate Cancer",
        "Metastatic Disease"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Casodex (bicalutamide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sandy Srinivas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 5,
      "start_date": "2009-10",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2014-10-13",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01020305"
    },
    {
      "nct_id": "NCT00634582",
      "title": "Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "paricalcitol",
          "type": "DRUG"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "dual x-ray absorptometry",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2009-01",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634582"
    },
    {
      "nct_id": "NCT00450619",
      "title": "153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Samarium Sm 153 lexidronam pentasodium",
          "type": "RADIATION"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant vaccinia-TRICOM vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant fowlpox-TRICOM vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2007-02",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-01-04",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Bethesda, Maryland • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00450619"
    },
    {
      "nct_id": "NCT01487863",
      "title": "Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Metastatic",
        "Hormone Refractory Prostate Cancer",
        "Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "sipuleucel-T",
          "type": "BIOLOGICAL"
        },
        {
          "name": "abiraterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dendreon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 69,
      "start_date": "2011-12",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 21,
      "location_summary": "La Jolla, California • La Mesa, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01487863"
    },
    {
      "nct_id": "NCT05848011",
      "title": "A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Androgen-Independent Prostatic Cancer",
        "Androgen-Independent Prostatic Neoplasms",
        "Prostate Cancer Recurrent",
        "Androgen-Insensitive Prostatic Cance",
        "Androgen-Resistant Prostatic Cancer",
        "Hormone Refractory Prostatic Cancer",
        "Immunotherapy",
        "Immune Checkpoint Inhibitor",
        "Inhibitory Checkpoint Molecule"
      ],
      "interventions": [
        {
          "name": "lorigerlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 154,
      "start_date": "2023-09-28",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-10T20:33:51.829Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Island",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05848011"
    }
  ]
}